866-997-4948(US-Canada Toll Free)

Schizophrenia - Pipeline Assessment and Market Forecast to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 50 Pages


GlobalData, the industry analysis specialist, has released its new report, “Schizophrenia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Schizophrenia market. The report identifies the key trends shaping and driving the global Schizophrenia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Schizophrenia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData estimated the global Schizophrenia market to be worth $6.7bn in 2009. The global Schizophrenia therapeutics market is forecast to decline with a CAGR of (3.7%) to reach $5.1bn by 2017. This decline in the market is primarily attributed to the release of generics of some of the leading products during 2011 to 2014. The therapeutic market for Schizophrenia declines form 2011 till mid 2014 due to the patent expiry of major marketed drugs such as Zyprexa, Abilify, Seroquel and Geodon. However in the late 2014 launch of few first in class molecules is expected which is likely to lower the impact of patent expiry. There is a huge unmet need in the current market in terms of safety and efficacy. Furthermore a low treatment seeking rate and low patient compliance rate will act as a barrier to market growth. 

Scope

The report provides information on the key drivers and challenges of the Schizophrenia market. Its scope includes:

  • Annualized global Schizophrenia market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Dopamine-serotonin receptor targetter, NMDA glutamate receptor blocker, Glycine transporter inhibitor, Cannabinoid receptor agonist and alpha-7 nicotinic receptor.
  • Analysis of the current and future competition in the global Schizophrenia market. Key market players covered are Pfizer, GSK, J&J, Merck, Eli Lily and H. Lundbeck.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Schizophrenia therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Schizophrenia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Schizophrenia market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Schizophrenia market landscape? - Identify, understand and capitalize.
Table of contents

1 Table of contents 2

1.1 List of Tables 4
1.2 List of Figures 4

2 Schizophrenia Therapeutics Market: Introduction 5
2.1 Overview 5
2.2 GlobalData Pipeline Report Guidance 6

3 Schizophrenia Therapeutics Market: Market Characterization 7
3.1 Schizophrenia Market Size 7
3.2 Schizophrenia Market Forecast and CAGR 8
3.3 Drivers and Barriers for the Schizophrenia Market 9
3.3.1 Drivers for the Schizophrenia Market 9
3.3.2 Barriers for the Schizophrenia Market 9
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 11

4 Schizophrenia Market: Competitive Assessment 12

4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Schizophrenia Market 13
4.3.1 Zyprexa (olanzapine) 13
4.3.2 Abilify (aripiprazole) 14
4.3.3 Seroquel/Seroquel XR (quetiapine) 15
4.3.4 Geodon (ziprasidone) 15
4.3.5 Invega (paliperidone) 16
4.3.6 Fanapt (iloperidone) 17
4.3.7 Saphris (asenapine) 18
4.3.8 Serdolect (sertindole) 19
4.4 Key Takeaway 21

5 Schizophrenia Market: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.2.1 Technology Trends Analytic Framework 22
5.3 Schizophrenia Therapeutics Promising Drugs under Clinical Development 23
5.4 Molecule Profile for Promising Drugs under Clinical Development 24
5.4.1 Lurasidone 24
5.4.2 Cariprazine (RGH-188) 24
5.4.3 LY2140023 25
5.4.4 Staccato Loxapine, AZ-004 26
5.5 Schizophrenia Therapeutics Market Clinical Pipeline by Mechanism of Action 27
5.6 Schizophrenia Pipeline Pipeline by Clinical Phases of Development 28
5.6.1 Schizophrenia Therapeutics Regulatory Clinical Pipeline 28
5.6.2 Schizophrenia Therapeutics Phase III Clinical Pipeline 29
5.6.3 Schizophrenia Therapeutics Phase II Clinical Pipeline 30
5.6.4 Schizophrenia Therapeutics Phase I Clinical Pipeline 32
5.6.5 Schizophrenia Therapeutics Preclinical and Discovery Pipeline 33
5.7 Key Takeaway 33

6 Schizophrenia Market: Implications for Future Market Competition 34

7 Schizophrenia Market: Future Players in the Schizophrenia Market 36

7.1 Introduction 36
7.2 Merck & Co 36
7.2.1 Company Overview 36
7.2.2 Financial Performance 37
7.2.3 Business Description 37
7.3 Pfizer Inc. 38
7.3.1 Company Overview 38
7.3.2 Business Description 39
7.4 GlaxoSmithKline 40
7.4.1 Company Overview 40
7.4.2 Financial Performance 40
7.4.3 Business Description 40
7.5 H Lundbeck A/S 42
7.5.1 Company Overview 42
7.5.2 Financial Performance 42
7.5.3 Business Description 42
7.6 Dainippon Sumitomo Pharma Co., Ltd. 43
7.6.1 Company Overview 43
7.6.2 Financial Performance 43
7.6.3 Business Description 43

8 Schizophrenia Market: Appendix 45
8.1 Market Definitions 45
8.2 Abbreviations 45
8.3 Research Methodology 46
8.3.1 Coverage 46
8.3.2 Secondary Research 46
8.3.3 Forecasting 46
8.3.4 Primary Research 49
8.3.5 Expert Panels Validation 49
8.4 Contact Us 49
8.5 Disclaimer 49
8.6 Sources 50

List of Table


Table 1: Schizophrenia Therapeutics Market, Global, Revenue ($bn), 20012009 7
Table 2: Schizophrenia Market, Global, Market Forecasts ($bn), 20092017 8
Table 3: Major Marketed Products Comparison in the Schizophrenia Market, 2010 20
Table 4: Schizophrenia Therapeutics Market, Global, Most Promising Molecules Under Clinical Development, 2010 23
Table 5: Schizophrenia Therapeutics NDA Filed Products, 2010 28
Table 6: Schizophrenia Therapeutics Phase III Clinical Pipeline, 2010 29
Table 7: Schizophrenia Therapeutics Phase II Clinical Pipeline, 2010 30
Table 8: Schizophrenia Therapeutics Phase I Clinical Pipeline, 2010 32
Table 9: Schizophrenia Therapeutics Preclinical and Discovery Pipeline, 2010 33
Table 10: Merck & Co Schizophrenia Pipeline Products, 2010 38
Table 11: Pfizer Schizophrenia Pipeline Products, 2010 40
Table 12: GSK Schizophrenia Pipeline Products, 2010 41
Table 13: H Lundbeck Schizophrenia Pipeline Products, 2010 43
Table 14: Dainippon Sumitomo Pharma Schizophrenia Pipeline Products, 2010 44

List of Chart


Figure 1: Schizophrenia Therapeutics Market, Global, Revenues ($bn), 2001- 2009 7
Figure 2: Schizophrenia Therapeutics Market, Global, Revenues ($bn), 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Schizophrenia Therapeutic Market, 2009 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Schizophrenia, 2010 13
Figure 5: Technology Trends Analytic Framework of the Schizophrenia Therapeutic Pipeline, 2010 22
Figure 6: Technology Trends Analytic Framework of the Schizophrenia Therapeutics Pipeline Description, 2010 23
Figure 7: Schizophrenia Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 27
Figure 8: Schizophrenia Therapeutics Pipeline by Phase of Clinical Development, 2010 28
Figure 9: Implications for Future Market Competition in the Schizophrenia Market, 2009 34
Figure 10: Schizophrenia Therapeutics Clinical Pipeline by Company, 2010 36
Figure 11: GlobalData Market Forecasting Model 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *